基于肿瘤异质性的转移性结直肠癌患者基因检测专家共识（2025版）

doi:10.3969/j.issn.1006-5725.2025.19.001

Abstract

Abstract:

Colorectal cancer is one of the most prevalent malignant tumors in China. Chemotherapy， targeted therapy， and immunotherapy constitute the primary treatment modalities for patients with metastatic colorectal cancer. With the advancement of precision medicine， next-generation gene sequencing has become an essential component of the diagnostic and therapeutic process for metastatic colorectal cancer. Gene sequencing results provide critical guidance for the formulation of individualized treatment strategies. However， colorectal cancer exhibits significant tumor heterogeneity. Within the same patient， genetic profiles may differ between primary and metastatic tumors， as well as between tumor tissues obtained before and after treatment. A comprehensive and accurate understanding of these genetic differences is crucial for optimizing treatment efficacy. To address this issue， the Multidisciplinary Diagnosis and Treatment Committee of the Guangdong Anti-Cancer Association convened a panel of domestic multidisciplinary experts to develop the Expert Consensus on Genetic Testing for Patients with Metastatic Colorectal Cancer Based on Tumor Heterogeneity （2025 Edition） following extensive discussions. This consensus aims to maximize patient treatment outcomes and enhance the overall standard of colorectal cancer diagnosis and management in China.

Key words: colorectal cancer, heterogeneity, gene sequencing, expert consensus

CLC Number:

R735.3

References 47

[1]	ENG C， YOSHINO T， RUIZ-GARCIA E， et al. Colorectal cancer ［J］. Lancet， 2024， 404（10449）： 294-310. doi:10.1016/s0140-6736(24)00360-x doi: 10.1016/s0140-6736(24)00360-x
[2]	JADAD A R， MOORE R A， CARROLL D， et al. Assessing the quality of reports of randomized clinical trials： Is blinding necessary？［J］. Control Clin Trials， 1996， 17（1）： 1-12. doi:10.1016/0197-2456(95)00134-4 doi: 10.1016/0197-2456(95)00134-4
[3]	DESAI A P， GO R S， POONACHA T K. Category of evidence and consensus underlying National Comprehensive Cancer Network guidelines： Is there evidence of progress？［J］. Int J Cancer， 2021， 148（2）： 429-436. doi:10.1002/ijc.33215 doi: 10.1002/ijc.33215
[4]	中华人民共和国国家卫生健康委员会，中华医学会肿瘤学分会. 中国结直肠癌诊疗规范（2023年版）［J］. 中华外科杂志， 2023， 61（8）： 617-644.
[5]	YANG J， PENG J Y， CHEN W. Synchronous colorectal cancers： A review of clinical features， diagnosis， treatment， and prognosis ［J］. Dig Surg， 2011， 28（516）： 379-385. doi:10.1159/000334073 doi: 10.1159/000334073
[6]	国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院. 防癌体检结直肠癌筛查技术应用专家共识［J］. 中华健康管理学杂志， 2024， 18（11）： 805-815.
[7]	ZHAO Y， WU J， PEI F， et al. Molecular Typing and Clinical Characteristics of Synchronous Multiple Primary Colorectal Cancer ［J］. JAMA Netw Open， 2022， 5（11）： e2243457. doi:10.1001/jamanetworkopen.2022.43457 doi: 10.1001/jamanetworkopen.2022.43457
[8]	PEARLMAN R， FRANKEL W L， SWANSON B， et al. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer ［J］. JAMA Oncol， 2017， 3（4）： 464-471. doi:10.1001/jamaoncol.2016.5194 doi: 10.1001/jamaoncol.2016.5194
[9]	GIANNINI R， LUPI C， LOUPAKIS F， et al. KRAS and BRAF genotyping of synchronous colorectal carcinomas ［J］. Oncol Lett， 2014， 7（5）： 1532-1536. doi:10.3892/ol.2014.1905 doi: 10.3892/ol.2014.1905
[10]	LEE H G， KIM Y， KIM M J， et al. Molecular Mosaics： Unveiling Heterogeneity in Synchronous Colorectal Cancers ［J］. Cancer Res Treat， 2025.doi： 10.4143/crt.2024.947 . doi: 10.4143/crt.2024.947
[11]	LU B， LUO J， YAN Y， et al. Evaluation of long-term benefits and cost-effectiveness of nation-wide colorectal cancer screening strategies in China in 2020-2060： A modelling analysis ［J］. Lancet Reg Health West Pac， 2024， 51： 101172. doi:10.1016/j.lanwpc.2024.101172 doi: 10.1016/j.lanwpc.2024.101172
[12]	BHULLAR D S， BARRIUSO J， MULLAMITHA S， et al. Biomarker concordance between primary colorectal cancer and its metastases ［J］. EBioMedicine， 2019， 40： 363-374. doi:10.1016/j.ebiom.2019.01.050 doi: 10.1016/j.ebiom.2019.01.050
[13]	LEE S E， PARK H Y， HWANG D Y， et al. High Concordance of Genomic Profiles between Primary and Metastatic Colorectal Cancer ［J］. Int J Mol Sci， 2021， 22（11）： 5561. doi:10.3390/ijms22115561 doi: 10.3390/ijms22115561
[14]	LI C， SUN Y D， YU G Y， et al. Integrated Omics of Metastatic Colorectal Cancer ［J］. Cancer Cell， 2020， 38（5）： 734-747. e9. doi:10.1016/j.ccell.2020.08.002 doi: 10.1016/j.ccell.2020.08.002
[15]	SCHIRRIPA M， BIASON P， LONARDI S， et al. Class 1， 2， and 3 BRAF-Mutated Metastatic Colorectal Cancer： A Detailed Clinical， Pathologic， and Molecular Characterization ［J］. Clin Cancer Res， 2019， 25（13）： 3954-3961. doi:10.1158/1078-0432.ccr-19-0311 doi: 10.1158/1078-0432.ccr-19-0311
[16]	CIOMBOR K K， STRICKLER J H， BEKAII-SAAB T S， et al. BRAF-Mutated Advanced Colorectal Cancer： A Rapidly Changing Therapeutic Landscape ［J］. J Clin Oncol， 2022， 40（24）： 2706-2715. doi:10.1200/jco.21.02541 doi: 10.1200/jco.21.02541
[17]	HUANG Q， YU T， LI L， et al. Intraindividual Tumor Heterogeneity of Mismatch Repair Status in Metastatic Colorectal Cancer ［J］. Appl Immunohistochem Mol Morphol， 2023， 31（2）： 84-93. doi:10.1097/pai.0000000000001089 doi: 10.1097/pai.0000000000001089
[18]	WANG Z， TANG X， WU X， et al. Mismatch repair status between primary colorectal tumor and metastatic tumor， a retrospective consistent study ［J］. Biosci Rep， 2019， 39（12）： BSR20190730. doi:10.1042/bsr20190730 doi: 10.1042/bsr20190730
[19]	ONG J C， ZHAO J J， LIU Y， et al. Spatial heterogeneity， stromal phenotypes， and therapeutic vulnerabilities in colorectal cancer peritoneal metastasis ［J］. Clin Cancer Res， 2025， 31（12）： 2515-2529. doi:10.1158/1078-0432.ccr-24-3780 doi: 10.1158/1078-0432.ccr-24-3780
[20]	FUJIYOSHI K， YAMAMOTO G， TAKAHASHI A， et al. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases ［J］. Oncol Rep， 2017， 37（2）： 785-792. doi:10.3892/or.2016.5323 doi: 10.3892/or.2016.5323
[21]	HE W Z， HU W M， WANG F， et al. Comparison of Mismatch Repair Status Between Primary and Matched Metastatic Sites in Patients With Colorectal Cancer ［J］. J Natl Compr Canc Netw， 2019， 17（10）： 1174-1183. doi:10.6004/jnccn.2019.7308 doi: 10.6004/jnccn.2019.7308
[22]	HASHIMOTO T， TAKAYANAGI D， YONEMARU J， et al. A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer ［J］. Br J Cancer， 2023， 129（7）： 1176-1183. doi:10.1038/s41416-023-02382-z doi: 10.1038/s41416-023-02382-z
[23]	LEE W S， PARK Y H， LEE J N， et al. Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases ［J］. Cancer Med， 2014， 3（3）： 674-680. doi:10.1002/cam4.228 doi: 10.1002/cam4.228
[24]	SHAN L， LV Y， BAI B， et al. Variability in HER2 expression between primary colorectal cancer and corresponding metastases ［J］. J Cancer Res Clin Oncol， 2018， 144（11）： 2275-2281. doi:10.1007/s00432-018-2744-z doi: 10.1007/s00432-018-2744-z
[25]	TAN R Y C， CAMAT M D， NG M， et al. HER2 positive rates are enriched amongst colorectal cancer brain metastases： A study amongst 1920 consecutive patients ［J］. Ann Oncol， 2018， 29（7）： 1598-1599. doi:10.1093/annonc/mdy156 doi: 10.1093/annonc/mdy156
[26]	PIETRANTONIO F， DI NICOLANTONIO F， SCHROCK A B， et al. ALK， ROS1， and NTRK Rearrangements in Metastatic Colorectal Cancer ［J］. J Natl Cancer Inst， 2017， 109（12）：djx089. doi:10.1093/jnci/djx089 doi: 10.1093/jnci/djx089
[27]	GUO Y， GUO X L， WANG S， et al. Genomic Alterations of NTRK， POLE， ERBB2， and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer ［J］. Oncologist， 2020， 25（11）： e1671-e1680. doi:10.1634/theoncologist.2020-0356 doi: 10.1634/theoncologist.2020-0356
[28]	AISNER D L， NGUYEN T T， PASKULIN D D， et al. ROS1 and ALK fusions in colorectal cancer， with evidence of intratumoral heterogeneity for molecular drivers ［J］. Mol Cancer Res， 2014， 12（1）： 111-118. doi:10.1158/1541-7786.mcr-13-0479-t doi: 10.1158/1541-7786.mcr-13-0479-t
[29]	WEI Q， YE Z， ZHONG X， et al. Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis ［J］. Ann Oncol， 2017， 28（9）： 2135-2141. doi:10.1093/annonc/mdx278 doi: 10.1093/annonc/mdx278
[30]	BENSON A B， VENOOK A P， ADAM M， et al. Colon Cancer， Version 3.2024， NCCN Clinical Practice Guidelines in Oncology ［J］. J Natl Compr Canc Netw， 2024， 22（2 D）： e240029.
[31]	BERTOTTI A， PAPP E， JONES S， et al. The genomic landscape of response to EGFR blockade in colorectal cancer ［J］. Nature， 2015， 526（7572）： 263-267. doi:10.1038/nature14969 doi: 10.1038/nature14969
[32]	OSUMI H， VECCHIONE L， KEILHOLZ U， et al. NeoRAS wild-type in metastatic colorectal cancer： Myth or truth？-Case series and review of the literature ［J］. Eur J Cancer， 2021， 153： 86-95. doi:10.1016/j.ejca.2021.05.010 doi: 10.1016/j.ejca.2021.05.010
[33]	GAZZANIGA P， RAIMONDI C， NICOLAZZO C， et al. ctDNA might expand therapeutic options for second line treatment of KRAS mutant mCRC ［J］. Ann Oncol， 2017， 28： v586. doi:10.1093/annonc/mdx390.044 doi: 10.1093/annonc/mdx390.044
[34]	GAZZANIGA P， RAIMONDI C， URBANO F， et al. Second line EGFR-inhibitors in RAS mutant metastatic colorectal cancer： The plasma RAS wild type "window of opportunity" ［J］. Ann Oncol， 2018， 29（）： viii183-viii184. doi:10.1093/annonc/mdy281.095 doi: 10.1093/annonc/mdy281.095
[35]	OSUMI H， SHINOZAKI E， NAKAMURA Y， et al. Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy ［J］. Nat Commun， 2024， 15（1）： 5885. doi:10.1038/s41467-024-50026-4 doi: 10.1038/s41467-024-50026-4
[36]	GAZZANIGA P， RAIMONDI C， URBANO F， et al. EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant RAS Metastatic Colorectal Cancer： Circulating Tumor DNA to Personalize Treatment ［J］. JCO Precis Oncol， 2018， 2： 1-6. doi:10.1200/po.17.00277 doi: 10.1200/po.17.00277
[37]	MORELLI M P， OVERMAN M J， DASARI A， et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment ［J］. Ann Oncol， 2015， 26（4）： 731-736. doi:10.1093/annonc/mdv005 doi: 10.1093/annonc/mdv005
[38]	SANTINI D， VINCENZI B， ADDEO R， et al. Cetuximab rechallenge in metastatic colorectal cancer patients： How to come away from acquired resistance？［J］. Ann Oncol， 2012， 23（9）： 2313-2318. doi:10.1093/annonc/mdr623 doi: 10.1093/annonc/mdr623
[39]	SCLAFANI F， GONZALEZ D， CUNNINGHAM D， et al. RAS mutations and cetuximab in locally advanced rectal cancer： Results of the EXPERT-C trial ［J］. Eur J Cancer， 2014， 50（8）： 1430-1436. doi:10.1016/j.ejca.2014.02.002 doi: 10.1016/j.ejca.2014.02.002
[40]	NAPOLITANO S， DE FALCO V， MARTINI G， et al. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer： A Phase 2 Randomized Clinical Trial ［J］. JAMA Oncol， 2023， 9（7）： 966-970. doi:10.1001/jamaoncol.2023.0655 doi: 10.1001/jamaoncol.2023.0655
[41]	SINGHAL A， LI B T， O'REILLY E M. Targeting KRAS in cancer ［J］. Nat Med， 2024， 30（4）： 969-983. doi:10.1038/s41591-024-02903-0 doi: 10.1038/s41591-024-02903-0
[42]	YAEGER R， UBOHA N V， PELSTER M S， et al. Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer ［J］. Cancer Discov， 2024， 14（6）： 982-993. doi:10.1158/2159-8290.cd-24-0217 doi: 10.1158/2159-8290.cd-24-0217
[43]	AWAD M M， LIU S， RYBKIN， II， et al. Acquired Resistance to KRAS（G12C） Inhibition in Cancer ［J］. N Engl J Med， 2021， 384（25）： 2382-2393. doi:10.1056/nejmoa2105281 doi: 10.1056/nejmoa2105281
[44]	YAEGER R， MEZZADRA R， SINOPOLI J， et al. Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer ［J］. Cancer Discov， 2023， 13（1）： 41-55. doi:10.1158/2159-8290.cd-22-0405 doi: 10.1158/2159-8290.cd-22-0405
[45]	ANDRE T， SHIU K K， KIM T W， et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer： 5-year follow-up from the randomized phase Ⅲ KEYNOTE-177 study ［J］. Ann Oncol， 2025， 36（3）： 277-284. doi:10.1016/j.annonc.2024.11.012 doi: 10.1016/j.annonc.2024.11.012
[46]	ZHANG J， ZHANG X， WANG Q， et al. Histomorphological and molecular genetic characterization of different intratumoral regions and matched metastatic lymph nodes of colorectal cancer with heterogenous mismatch repair protein expression ［J］. J Cancer Res Clin Oncol， 2023， 149（7）： 3423-3434. doi:10.1007/s00432-022-04261-1 doi: 10.1007/s00432-022-04261-1
[47]	BIELSKA A A， CHATILA W K， WALCH H， et al. Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance ［J］. J Natl Compr Canc Netw， 2021， 19（2）： 130-133. doi:10.6004/jnccn.2020.7680 doi: 10.6004/jnccn.2020.7680

Expert consensus on genetic testing for metastatic colorectal cancer patients based on tumor heterogeneity

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 47

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Na WU,Zetian ZHANG,Rui WANG. The expression and clinical significance of B7⁃H3， PRDX1， and TRX in the serum and tissues of patients with ulcerative colitis and its related colorectal cancer [J]. The Journal of Practical Medicine, 2025, 41(9): 1407-1412.
[2]	Likun WANG,Qi HAO,Weihan JIN,Shizheng DONG,Xueliang WU,Xiaofeng HU,Liang WU,Jing XUN,Hongqing MA. Application of multi⁃omics and artificial intelligence in the prediction and diagnosis of liver metastases in colorectal cancer [J]. The Journal of Practical Medicine, 2025, 41(7): 1070-1078.
[3]	Linsha KONG,Gaigai HE,Ting LI,Kun FANG,Wei HE,Li WEI. Experimental study of doxorubicin coated by magnetic drug⁃carrying gel beads in the treatment of colorectal cancer [J]. The Journal of Practical Medicine, 2025, 41(7): 953-959.
[4]	Wei WANG,Min WANG,Minmin CHENG,Tingting. ZHANG. Impacts of safflower polysaccharide on tumor growth and PI3K/Akt/mTOR signal pathway in mice with colorectal cancer [J]. The Journal of Practical Medicine, 2025, 41(5): 670-675.
[5]	Jiyue ZHU,Bo ZHANG,Yaru LI,Liuye. HUANG. The predictive value of the systemic inflammation response index for non⁃curative resection after endoscopic submucosal dissection for early colorectal cancer [J]. The Journal of Practical Medicine, 2025, 41(5): 716-723.
[6]	Cuicui WANG,Wantong QIAO,Junying YAO,Qian LI,Weige GAO,Min FAN. Clinical application value of nutritional control status score combined with prognostic nutritional index in evaluating the risk of anemia in elderly colorectal cancer patients [J]. The Journal of Practical Medicine, 2025, 41(17): 2696-2704.
[7]	Mengying ZHANG,Yaokai MA,Yifan DU,Wei ZHANG,Bo ZHOU,Xiyi YANG. A Randomized controlled study on the efficacy of HAIC sequential DEB⁃TACE in the treatment of colorectal cancer liver metastasis [J]. The Journal of Practical Medicine, 2025, 41(17): 2721-2728.
[8]	Yi LU,Shilong DAI,Mingjun WANG,Jing ZHOU,Junying HAO,Chen ZHENG,Xinbo XU,Shan DING,Qingsong ZHANG. The relationship between the triglyceride⁃glucose index and its modified index and colorectal cancer： A prospective cohort study [J]. The Journal of Practical Medicine, 2025, 41(15): 2362-2371.
[9]	Qisen FAN,Lan LAN,Jingxiang WU,Yuan QIU,Guiping XU,Jiang WANG,Duozhi WU,Jinhui LUO,Jian RAN,Yingfen LI,Peng PAN,Bing ZHANG,Yuelan ZHOU,Yiwen ZHANG,Xuebing XU,Yatao LIU,Yingbin WANG,Yan WANG,Yulong WANG,Youyang HU,Shoushi WANG,Hongwei MENG,Haixia XU,Peijia TANG,Xiaoxue ZHUANG,Canzhou. ZHANG. Consensus of experts on the management of thoracic anesthesia with spontaneous respiration [J]. The Journal of Practical Medicine, 2025, 41(13): 1945-1951.
[10]	Zeping HE,Junming XU. The role and prognostic value of matrix metalloproteinase 19 in colorectal cancer and its liver metastasis [J]. The Journal of Practical Medicine, 2025, 41(13): 1987-1996.
[11]	Long WANG,Yingmin WU,Sha SHANG,Lu WANG. The diagnostic value and clinical research of 5′⁃tRF⁃GlyGCC in the early stage of colorectal cancer [J]. The Journal of Practical Medicine, 2025, 41(11): 1730-1735.
[12]	Xiao YANG,Tao WANG,Wei WANG,Yaohui PENG,Yan CHEN,Haiping ZENG,Bao YANG. Lipidomic profile of serum in colorectal cancer patients and its diagnostic significance [J]. The Journal of Practical Medicine, 2025, 41(11): 1742-1750.
[13]	Wenying SHANG,Die LONG,Haihui CHEN. Real⁃world analysis of the differences between left and right colorectal cancer based on clinical pathological characteristics and gene testing results [J]. The Journal of Practical Medicine, 2025, 41(1): 48-52.
[14]	Yuxuan DING,Lining GUO,Jiayi SHEN,Lijun. WANG. Safety and efficacy of radiotherapy and PD⁃1/PD⁃L1 inhibitor + TKI for MSS/pMMR colorectal cancer with liver metastases [J]. The Journal of Practical Medicine, 2024, 40(9): 1293-1297.
[15]	Xiya MA,Hu JI,Zehua ZHU,Bo PAN,Qiang XIE,Xiaobo. YAO. The predictive value of ¹⁸F⁃FDG PET/CT metabolic heterogeneity parameters combined with clinical features for the prognosis of esophageal squamous cell carcinoma before definitive radiochemotherapy [J]. The Journal of Practical Medicine, 2024, 40(7): 966-971.